MiMedx Group, Inc. (NASDAQ:MDXG) CAO William Frank Iv Hulse Sells 81,446 Shares

MiMedx Group, Inc. (NASDAQ:MDXG) CAO William Frank Iv Hulse sold 81,446 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $7.80, for a total value of $635,278.80. Following the transaction, the chief accounting officer now owns 494,774 shares of the company’s stock, valued at $3,859,237.20. This trade represents a 14.13 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

MiMedx Group Trading Down 0.2 %

Shares of MDXG stock opened at $8.10 on Thursday. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. The company has a market cap of $1.19 billion, a price-to-earnings ratio of 14.73 and a beta of 1.97. The stock has a 50 day simple moving average of $8.51 and a 200-day simple moving average of $7.80. MiMedx Group, Inc. has a 1-year low of $5.47 and a 1-year high of $10.14.

MiMedx Group (NASDAQ:MDXG) last issued its earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.07. The company had revenue of $92.91 million during the quarter, compared to analysts’ expectations of $89.42 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. On average, equities research analysts expect that MiMedx Group, Inc. will post 0.3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reissued an “overweight” rating and set a $13.00 target price on shares of MiMedx Group in a research report on Thursday, February 27th.

Hedge Funds Weigh In On MiMedx Group

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. IMG Wealth Management Inc. acquired a new stake in MiMedx Group in the 4th quarter valued at about $28,000. Virtus Fund Advisers LLC purchased a new position in shares of MiMedx Group in the 4th quarter valued at approximately $35,000. Van ECK Associates Corp purchased a new position in shares of MiMedx Group in the 4th quarter valued at approximately $40,000. Point72 DIFC Ltd boosted its stake in shares of MiMedx Group by 127.6% in the third quarter. Point72 DIFC Ltd now owns 7,626 shares of the company’s stock valued at $45,000 after buying an additional 4,275 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in shares of MiMedx Group by 77.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company’s stock worth $63,000 after purchasing an additional 2,837 shares during the period. 79.15% of the stock is currently owned by hedge funds and other institutional investors.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.